Spots Global Cancer Trial Database for tecemotide
Every month we try and update this database with for tecemotide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy | NCT00960115 | Non-small Cell ... | Tecemotide (L-B... Single low dose... Placebo Saline | 20 Years - | Merck KGaA, Darmstadt, Germany | |
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer | NCT02049151 | Carcinoma, Non-... | Tecemotide Placebo Cyclophosphamid... Saline (sodium ... | 18 Years - | EMD Serono | |
Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population | NCT01015443 | Non-Small Cell ... | Tecemotide Single low dose... Placebo Saline Best Supportive... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
Tecemotide (L-BLP25) in Prostate Cancer | NCT01496131 | Prostate Cancer | Radiation thera... Goserelin Cyclophosphamid... Tecemotide (L-B... | 18 Years - | EMD Serono | |
Common Safety Follow-up Trial of Tecemotide (L-BLP25) | NCT01423760 | Non-Small Cell ... Multiple Myelom... | Tecemotide No intervention | 18 Years - | Merck KGaA, Darmstadt, Germany | |
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | NCT00828009 | Lung Cancer | bevacizumab Tecemotide carboplatin cyclophosphamid... paclitaxel radiotherapy | 18 Years - | Eastern Cooperative Oncology Group | |
Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population | NCT01015443 | Non-Small Cell ... | Tecemotide Single low dose... Placebo Saline Best Supportive... | 18 Years - | Merck KGaA, Darmstadt, Germany |